Plasminogen Activator Inhibitor-1

Background

Creative Biolabs provides a wide range of high-quality aptamers targeting plasminogen activator inhibitor-1 to help researchers improve their experiments and research. We aim to help you improve your experiments and accelerate the research and development processes.

Introduction

PAI-1 stands for plasminogen activator inhibitor-1. It is the primary substance that inhibits fibrinolytic activity in the blood circulation. PAI-1 plays a crucial role in inhibiting t-PA and u-PA, referring to tissue plasminogen activator and urokinase plasminogen activator, respectively. The cleavage of fibrinogen to create fibrinolytic enzymes is carried out by u-PA. PAI-1 inhibits u-PA through active site binding, thus preventing the formation of fibrinolytic enzymes. The dynamic balance between t-PA and PAI-1 plays a decisive role in maintaining the homeostasis of the plasma fibrinolytic system. PAI-1 can also inhibit the hydrolysis of fibrin by PA, affecting smooth muscle cell migration, tissue repair, collagenase activation, and tumor growth and metastasis. In addition, it also affects the remodeling process after vascular injury. Peak activity during the winter and in the morning is observed in PA-1, while its activity reaches its lowest point during the summer and in the afternoon and evening. This may be the reason why fibrinolytic activity decreases and then causes myocardial infarction to occur in the early morning, which is consistent with the fact that the incidence of cardiovascular and cerebrovascular events is highest in the early morning and winter.

Fig.1 PAI-1 in the regulation of fibrinolysis.^1,3

PAI-1 in Diseases

Reducing the fibrinolytic system in the human plasma has been linked to cardiovascular disease. Elevated PAI-1 activity in the plasma has been identified as a factor increasing the chance of experiencing another heart attack. Research has demonstrated a significant link between higher PAI-1 levels and a heightened risk of heart attack in middle-aged patients, regardless of other common risk factors. At the same time, PAI-1 also impacts deep vein thrombosis, intimal formation and restenosis, and angiogenesis. In addition, increased expression of PAI-1 is found in atherosclerotic vessel walls and atherosclerotic lesions, which may promote thrombosis in the event of plaque rupture.

The plasminogen activator system significantly impacts the advancement of tumors, the invasion of tumors, and the development of metastases. It has been shown that high PAI-1 levels indicate poor prognosis in breast cancer, cancer, urinary tract tumors, and cancer. The measurement of PAI-1 in tumor tissue is an important prognostic parameter for various malignant diseases. By regulating cell adhesion, migration, and cell invasiveness, PAI-1 can affect the evolution of tumors.

Creative Biolabs provides various plasminogen activator inhibitor-1 products to fulfill your diverse experimental requirements.

PAI-1 Aptamer Analysis

Anti-PAI-1 aptamers are oligonucleotides that specifically bind to PAI-1, a key regulator of fibrinolysis. These aptamers target specific binding sites on PAI-1, inhibiting its activity. They play a crucial role in modulating blood clotting and have diverse applications, including in diagnostics for cardiovascular diseases, cancer, and fibrosis, as well as in therapeutic interventions to regulate PAI-1 activity for disease management.

PAI-1-specific aptamer inhibitors have been shown to disrupt the interaction of PAI-1 with heparin/vitronectin. Subsequently, newly developed anti-PAI-1 RNA aptamers can inhibit its antiproteolytic activity and disrupt the interaction between PAI-1 and tPA. In addition, anti-PAI-1 aptamers, whether administered externally or expressed endogenously, can modulate cell migration, adhesion, and angiogenesis, which is associated with an increased association of PAI-1 with uPA.

Fig.2 Intracellular aptamers inhibit uPA activity.^2,3

Studies emphasize the potential of anti-PAI-1 aptamers in a range of diagnostic and therapeutic applications. For instance, studies have explored their use in detecting elevated PAI-1 levels in plasma samples, aiding in the early diagnosis of cardiovascular conditions. Additionally, aptamers can be potential therapeutic agents for inhibiting PAI-1 activity, which could help manage diseases related to abnormal fibrinolysis, such as thrombosis, atherosclerosis, and fibrosis. Studies have found that there is an aptamer-dependent reduction in migration and invasion of breast cancer cells, and anti-PAI-1 aptamers show therapeutic potential as antimetastatic agents and may be used as adjuvants to conventional chemotherapy for breast cancer.

Creative Biolabs provides customized high-specificity and potency anti-PAI-1 aptamer products, and tailored services for various research applications, ensuring quality solutions for our customers.

References

1. Mennesson, Marie, and Jean-Michel Revest. "Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders." International Journal of Molecular Sciences 24.5 (2023): 4496.
2. Fortenberry, Yolanda M., et al. "Intracellular expression of PAI-1 specific aptamers alters breast cancer cell migration, invasion and angiogenesis." PLoS One 11.10 (2016): e0164288.
3. Distributed under Open Access license CC BY 4.0, without modification.